Acutus Medical Announces CE Mark Approval for Suite of Next Generation EP Products in Europe
Expanded and Product Portfolio Strengthens Offering in Access and Therapy Guidance
May 12, 2021 16:05 ET | Source: Acutus Medical, Inc. Acutus Medical, Inc. Carlsbad, California, UNITED STATES
CARLSBAD, Calif., May 12, 2021 (GLOBE NEWSWIRE) Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced CE Mark Approval for a broad suite of EP products that includes the AcQCross™ family of universal transseptal crossing devices, the next generation AcQGuide
® MAX and VUE large bore delivery sheaths and the next generation AcQMap